fenfluramine has been researched along with Obsessive-Compulsive Disorder in 28 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
Obsessive-Compulsive Disorder: An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to evaluate serotonergic function in obsessive-compulsive disorder (OCD), plasma cortisol response to d-fenfluramine (30 mg p." | 9.08 | Cortisol response to d-fenfluramine in patients with obsessive-compulsive disorder and in healthy subjects: evidence for a gender-related effect. ( Catapano, F; Maj, M; Monteleone, P; Tortorella, A, 1997) |
| "Neuroendocrine and behavioral responses to a single 60-mg oral dose of the indirect serotonin agonist dl-fenfluramine were assessed in unmedicated adults with obsessive-compulsive disorder (OCD) and neuroendocrine results contrasted with those in normal control subjects." | 9.07 | Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonist dl-fenfluramine in adults with obsessive-compulsive disorder. ( DeMeo, MD; Halper, J; Mann, JJ; McBride, PA; Shear, MK; Sweeney, JA, 1992) |
| "Cortisol and prolactin responses to d-fenfluramine were measured in 10 drug-free normothymic patients with obsessive-compulsive disorder (OCD)." | 7.68 | Cortisol and prolactin responses to d-fenfluramine in non-depressed patients with obsessive-compulsive disorder: a comparison with depressed and healthy controls. ( Butcher, G; Clare, AW; Dinan, TG; Lucey, JV; O'Keane, V, 1992) |
| "of D-fenfluramine were measured over a 5 h period." | 5.29 | Serotonin activity in anorexia nervosa after long-term weight restoration: response to D-fenfluramine challenge. ( Lucey, JV; O'Dwyer, AM; Russell, GF, 1996) |
| "In order to evaluate serotonergic function in obsessive-compulsive disorder (OCD), plasma cortisol response to d-fenfluramine (30 mg p." | 5.08 | Cortisol response to d-fenfluramine in patients with obsessive-compulsive disorder and in healthy subjects: evidence for a gender-related effect. ( Catapano, F; Maj, M; Monteleone, P; Tortorella, A, 1997) |
| "Neuroendocrine and behavioral responses to a single 60-mg oral dose of the indirect serotonin agonist dl-fenfluramine were assessed in unmedicated adults with obsessive-compulsive disorder (OCD) and neuroendocrine results contrasted with those in normal control subjects." | 5.07 | Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonist dl-fenfluramine in adults with obsessive-compulsive disorder. ( DeMeo, MD; Halper, J; Mann, JJ; McBride, PA; Shear, MK; Sweeney, JA, 1992) |
| "The prolactin (PRL) responses to oral d-fenfluramine (30 mg) and placebo were assessed in 13 patients with obsessive-compulsive disorder (OCD) and in matched healthy subjects." | 3.69 | Plasma prolactin response to d-fenfluramine in obsessive-compulsive patients before and after fluvoxamine treatment. ( Bortolotti, F; Catapano, F; Maj, M; Monteleone, P, 1997) |
| "The prolactin and thyroid-stimulating hormone (TSH) responses to protirelin and the prolactin and cortisol responses to d-fenfluramine were measured in 8 outpatients with DSM-III-R obsessive-compulsive disorder (OCD)." | 3.68 | The anterior pituitary responds normally to protirelin in obsessive-compulsive disorder: evidence to support a neuroendocrine serotonergic deficit. ( Butcher, G; Clare, AW; Dinan, TG; Lucey, JV, 1993) |
| "Cortisol and prolactin responses to d-fenfluramine were measured in 10 drug-free normothymic patients with obsessive-compulsive disorder (OCD)." | 3.68 | Cortisol and prolactin responses to d-fenfluramine in non-depressed patients with obsessive-compulsive disorder: a comparison with depressed and healthy controls. ( Butcher, G; Clare, AW; Dinan, TG; Lucey, JV; O'Keane, V, 1992) |
| "Canine acral lick dermatitis is a naturally occurring disorder in which excessive licking of paws or flank can produce ulcers and infection that require medical treatment." | 2.67 | Drug treatment of canine acral lick. An animal model of obsessive-compulsive disorder. ( Kriete, M; Rapoport, JL; Ryland, DH, 1992) |
| "improves the core features of autism (social interaction, communication and behavioural problems);2." | 2.49 | Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). ( Brignell, A; Hazell, P; Randall, M; Silove, N; Williams, K, 2013) |
| "improves the core features of autism (social interaction, communication and behavioural problems); 2." | 2.46 | Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). ( Hazell, P; Silove, N; Wheeler, DM; Williams, K, 2010) |
| "of D-fenfluramine were measured over a 5 h period." | 1.29 | Serotonin activity in anorexia nervosa after long-term weight restoration: response to D-fenfluramine challenge. ( Lucey, JV; O'Dwyer, AM; Russell, GF, 1996) |
| "Symptoms were divided into paraphilias, nonparaphilic sexual addictions, and sexual obsessions." | 1.28 | Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias. ( Anthony, DT; Fallon, BA; Hollander, E; Klein, DF; Liebowitz, MR; Schneier, FR; Stein, DJ, 1992) |
| "Fenfluramine is a serotonin releaser and reuptake blocker which is marketed as an anorectic agent." | 1.28 | Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. ( DeCaria, CM; Hollander, E; Klein, DF; Liebowitz, MR; Schneier, FR; Schneier, HA, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.14) | 18.7374 |
| 1990's | 24 (85.71) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Williams, K | 2 |
| Brignell, A | 1 |
| Randall, M | 1 |
| Silove, N | 2 |
| Hazell, P | 2 |
| Wheeler, DM | 1 |
| Jenike, MA | 1 |
| Rauch, SL | 1 |
| Hollander, E | 7 |
| Cohen, LJ | 1 |
| DeCaria, C | 1 |
| Saoud, JB | 2 |
| Stein, DJ | 3 |
| Cooper, TB | 3 |
| Islam, NN | 1 |
| Liebowitz, MR | 7 |
| Klein, DF | 4 |
| Goodman, WK | 1 |
| McDougle, CJ | 3 |
| Barr, LC | 1 |
| Aronson, SC | 1 |
| Price, LH | 2 |
| Lucey, JV | 3 |
| Butcher, G | 2 |
| Clare, AW | 2 |
| Dinan, TG | 2 |
| O'Dwyer, AM | 1 |
| Russell, GF | 1 |
| Carpenter, LL | 1 |
| Epperson, CN | 1 |
| Monteleone, P | 3 |
| Catapano, F | 3 |
| Tortorella, A | 1 |
| Maj, M | 3 |
| Bortolotti, F | 1 |
| Di Martino, S | 1 |
| Ferraro, C | 1 |
| Fineberg, NA | 1 |
| Roberts, A | 1 |
| Montgomery, SA | 1 |
| Cowen, PJ | 1 |
| Stahl, SM | 1 |
| Pidrman, V | 1 |
| Tůma, I | 1 |
| Ramasubbu, R | 1 |
| Baumgarten, HG | 1 |
| Grozdanovic, Z | 1 |
| McBride, PA | 1 |
| DeMeo, MD | 1 |
| Sweeney, JA | 1 |
| Halper, J | 1 |
| Mann, JJ | 1 |
| Shear, MK | 1 |
| Rapoport, JL | 1 |
| Ryland, DH | 1 |
| Kriete, M | 1 |
| Anthony, DT | 1 |
| Schneier, FR | 2 |
| Fallon, BA | 1 |
| O'Keane, V | 1 |
| Hewlett, WA | 1 |
| Vinogradov, S | 1 |
| Martin, K | 1 |
| Berman, S | 1 |
| Csernansky, JG | 1 |
| DeCaria, CM | 3 |
| Trungold, S | 1 |
| Stanley, M | 1 |
| Nitescu, A | 1 |
| Gully, R | 1 |
| Suckow, RF | 1 |
| Gorman, JM | 2 |
| Judd, FK | 1 |
| Chua, P | 1 |
| Lynch, C | 1 |
| Norman, T | 1 |
| Schneier, HA | 1 |
| Fay, M | 1 |
| Cohen, B | 1 |
| Campeas, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double Blind, Randomized, Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (FCT)[NCT02410902] | Phase 3 | 190 participants (Actual) | Interventional | 2015-05-13 | Completed | ||
| An Open-Label Extension Study of CM-AT for the Treatment of Children With Autism With All Levels of Fecal Chymotrypsin[NCT02649959] | Phase 3 | 405 participants (Anticipated) | Interventional | 2015-10-31 | Active, not recruiting | ||
| Initial Evaluation of Efficacy and Adverse Events of Single Lesions in Bilateral Ventral-capsular and Ventral Capsulotomy-striatal by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder[NCT02500888] | 10 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary outcome measurements to determine efficacy of treatment with CM-AT versus Placebo for changes in the Aberrant Behavior Checklist (ABC) - Community sub scale for Irritability/Agitation (ABC-I) between baseline (subject's initial measurement) and Week 12/Termination (subject's final measurement) visit. Participants were between 3 through to 6 years old inclusive and took 900mg CM-AT or Placebo three times daily. The ABC-I is one of five discrete sub scales measured by the ABC. The scale range is 0-45. A higher score reflects higher severity of symptoms (irritability). Scores are obtained via Parent Rated Questionnaire. Parents respond to a series of questions on a scale directly into an electronic data capture system (EDC), responding: 0 = not at all a problem 1 = the behavior is a problem but slight in degree 2 = the problem is moderately serious 3 = the problem is severe in degree. The score was automatically calculated by the EDC. (NCT02410902)
Timeframe: Screening through Week 12/Termination
| Intervention | units on a scale (Mean) |
|---|---|
| CM-AT | -8.0 |
| Placebo | -5.5 |
Secondary outcome measurements to determine efficacy of treatment with CM-AT versus Placebo for changes in the Aberrant Behavior Checklist- Community (ABC) sub scale for Lethargy / Social Withdrawal (ABC-L) between baseline (subject's initial measurement) and Week 12/Termination (subject's final measurement) visit. Participants were between 3 through to 6 years old inclusive and took 900mg CM-AT or Placebo three times daily. The ABC-L is one of five discrete sub scales measured by the ABC. The scale range is 0-48. A higher score reflects higher severity of symptoms (lethargy). Scores are obtained via Parent Rated Questionnaire. Parents respond to a series of questions on a scale directly into an electronic data capture system (EDC), responding: 0 = not at all a problem 1 = the behavior is a problem but slight in degree 2 = the problem is moderately serious 3 = the problem is severe in degree. (NCT02410902)
Timeframe: Screening through Week 12/Termination.
| Intervention | units on a scale (Mean) |
|---|---|
| CM-AT | -7.9 |
| Placebo | -6.6 |
7 reviews available for fenfluramine and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Child Development Disorders, Pervasive; Citalopram; Fe | 2013 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Managing the patient with treatment-resistant obsessive compulsive disorder: current strategies.
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Behavior Therapy; Buspirone; Clonazepam; Com | 1994 |
Biological approaches to treatment-resistant obsessive compulsive disorder.
Topics: Behavior Therapy; Buspirone; Clonazepam; Combined Modality Therapy; Decision Trees; Drug Therapy, Co | 1993 |
A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Adult; Aged; Antidepressive Agents; Buspirone; Child; Clomipramine; Clonazepam; Cos | 1996 |
Update on pharmacologic management of OCD: agents and augmentation.
Topics: Clinical Trials as Topic; Clozapine; Dopamine Agents; Drug Therapy, Combination; Female; Fenfluramin | 1997 |
Role of serotonin in obsessive-compulsive disorder.
Topics: Biogenic Monoamines; Fenfluramine; Humans; Neuropeptides; Obsessive-Compulsive Disorder; Piperazines | 1998 |
8 trials available for fenfluramine and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Cortisol response to d-fenfluramine in patients with obsessive-compulsive disorder and in healthy subjects: evidence for a gender-related effect.
Topics: Administration, Oral; Adolescent; Adult; Female; Fenfluramine; Humans; Hydrocortisone; Hypothalamo-H | 1997 |
Prolactin response to d-fenfluramine in obsessive-compulsive patients, and outcome of fluvoxamine treatment.
Topics: Adolescent; Adult; Biomarkers; Double-Blind Method; Female; Fenfluramine; Fluvoxamine; Humans; Male; | 1997 |
Fenfluramine challenge test in obsessive-compulsive disorder--first results.
Topics: Adult; Citalopram; Clomipramine; Double-Blind Method; Female; Fenfluramine; Humans; Male; Obsessive- | 1997 |
Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonist dl-fenfluramine in adults with obsessive-compulsive disorder.
Topics: Adult; Age Factors; Behavior; Female; Fenfluramine; Humans; Male; Middle Aged; Neurosecretory System | 1992 |
Drug treatment of canine acral lick. An animal model of obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Animals; Clomipramine; Dermatitis; Desipramine; Disease Models, Animal; Dog Disease | 1992 |
Effects of fenfluramine on plasma HVA in OCD.
Topics: Dopamine; Fenfluramine; Homovanillic Acid; Humans; Obsessive-Compulsive Disorder; Serotonin | 1992 |
Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Double-Blind Method; Down-Regulation; Female; Fenfluramine; | 1992 |
Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings.
Topics: Adult; Clonidine; Fenfluramine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Piperazine | 1988 |
13 other studies available for fenfluramine and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Timing of neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels in OCD.
Topics: Adult; Female; Fenfluramine; Humans; Hydrocortisone; Male; Obsessive-Compulsive Disorder; Piperazine | 1993 |
The anterior pituitary responds normally to protirelin in obsessive-compulsive disorder: evidence to support a neuroendocrine serotonergic deficit.
Topics: Adult; Female; Fenfluramine; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Obsessive | 1993 |
Serotonin activity in anorexia nervosa after long-term weight restoration: response to D-fenfluramine challenge.
Topics: Administration, Oral; Adult; Anorexia Nervosa; Body Weight; Comorbidity; Female; Fenfluramine; Follo | 1996 |
Plasma prolactin response to d-fenfluramine in obsessive-compulsive patients before and after fluvoxamine treatment.
Topics: Adolescent; Adult; Brain; Female; Fenfluramine; Fluvoxamine; Humans; Male; Middle Aged; Obsessive-Co | 1997 |
Brain 5-HT function in obsessive-compulsive disorder. Prolactin responses to d-fenfluramine.
Topics: Adult; Brain; Case-Control Studies; Female; Fenfluramine; Humans; Male; Middle Aged; Obsessive-Compu | 1997 |
Serotonin: it's possible to have too much of a good thing.
Topics: Bulimia; Depressive Disorder; Fenfluramine; Heart Valve Diseases; Humans; Obsessive-Compulsive Disor | 1997 |
Increased prolactin responses to d-fenfluramine in obsessive-compulsive disorder.
Topics: Anxiety Disorders; Fenfluramine; Humans; Obsessive-Compulsive Disorder; Prolactin; Serotonin Agents | 1998 |
Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias.
Topics: Adolescent; Adult; Behavior, Addictive; Clomipramine; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; | 1992 |
Cortisol and prolactin responses to d-fenfluramine in non-depressed patients with obsessive-compulsive disorder: a comparison with depressed and healthy controls.
Topics: Adult; Arousal; Brain; Depressive Disorder; Fenfluramine; Humans; Hydrocortisone; Male; Middle Aged; | 1992 |
Fenfluramine stimulation of prolactin in obsessive-compulsive disorder.
Topics: Adult; Female; Fenfluramine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Prolactin; Se | 1992 |
Fenfluramine augmentation of clomipramine treatment of obsessive compulsive disorder.
Topics: Adult; Clomipramine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, C | 1991 |
Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment.
Topics: Adult; Clomipramine; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenfluramine; | 1990 |
Augmentation of antiobsessional treatment with fenfluramine.
Topics: Adult; Drug Synergism; Drug Therapy, Combination; Fenfluramine; Fluvoxamine; Humans; Male; Obsessive | 1988 |